News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age
Photo of Andrew Armstrong taken from goodrx.com
Dec 15, 2023, 06:25

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute, shared on X/Twitter:

“Pleased to share our ARCHES analysis of efficacy, safety, and quality of life of enzalutamide (ENZA)/androgen-deprivation therapy (ADT) in men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by age (>75 vs <75) in the European Urology Oncology journal.”

For the article, click here.
Source: Andrew Armstrong/X

Andrew Armstrong androgen-deprivation therapy (ADT) ARCHES cancer Duke Cancer Institute enzalutamide (ENZA) European Urology Oncology Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) OncoDaily Oncology
Special Coverage
Blog
Jan 10, 2025, 19:29
Treatment of Pleural Mesothelioma: ASCO Guideline Update by Hedy L. Kindler et al.
Blog
Jan 10, 2025, 19:16
Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond - SPCC
Insight
Jan 10, 2025, 18:54
Toufic Kachaamy: An exciting session on Pancreatic Endoscopic Ablation by ASGE
Opinion
Jan 10, 2025, 18:33
5 Articles in Immunotherapy suggested by Wafik El-Deiry
Blog
Jan 10, 2025, 18:28
In Memory of Petra Feyer: A Leader in Oncological Supportive Care
Insight
Jan 10, 2025, 18:23
Nimbus Therapeutics Announced Key Clinical and Business Updates in Oncology Pipeline
Science
Jan 10, 2025, 18:15
Fiber Consumption Linked to Epigenetic Changes with Potential Anti-Cancer Effects
Insight
Jan 10, 2025, 18:08
OneOncology’ Oncology Quality Hub has been Approved by CMS as a Qualified Clinical Data Registry
Insight
Jan 10, 2025, 17:52
UCLA Study Reveals Endocan as a Key Target to Combat Glioblastoma's Growth and Therapy Resistance
Blog
Jan 10, 2025, 17:40
Supriya Peshin: Palliative Medicine Consultation Reduces Readmission Significantly in Certain Diagnoses
Insight
Jan 10, 2025, 17:38
Penilla Gunther: Proud to present another international conference by FOKUS Patient
Insight
Jan 10, 2025, 17:16
Fabrice André has been elected as the President of the ESMO for the term 2025-2026